Unknown

Dataset Information

0

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis.

ABSTRACT:

SUBMITTER: Le K 

PROVIDER: S-EPMC7955124 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.
| S-EPMC2941277 | biostudies-other
Unknown Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).
| S-EPMC6294449 | biostudies-other
Unknown Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
| S-EPMC8271116 | biostudies-literature
Unknown From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).
| S-EPMC5664077 | biostudies-literature
Unknown Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
| S-EPMC5924614 | biostudies-literature
Unknown Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
| S-EPMC3129369 | biostudies-literature
Unknown LncRNA PVT1 Facilitates Tumorigenesis and Progression of Glioma via Regulation of MiR-128-3p/GREM1 Axis and BMP Signaling Pathway.
| S-EPMC6277294 | biostudies-literature
Unknown lncRNA PVT1 Promotes Tumorigenesis of Colorectal Cancer by Stabilizing miR-16-5p and Interacting with the VEGFA/VEGFR1/AKT Axis.
| S-EPMC7139143 | biostudies-literature
Unknown Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
| S-EPMC5700232 | biostudies-literature
Unknown Non-Coding RNA Networks in ALK-Positive Anaplastic-Large Cell Lymphoma.
| S-EPMC6539248 | biostudies-literature